Program
ruvonoflast
Its studies are mostly in Obesity · Cardiovascular Diseases, led by Rezera (formerly NodThera Limited).
Furthest: phase 2, since May 30, 20253 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Rezera (formerly NodThera Limited) | 30 open or running | phase 2since May 30, 2025 | Oct 30, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 30, 2023First study: phase 1 study in Cardiovascular DiseasesFirst studyNCT06129409 · 67 enrolled · United States
- May 30, 2025Phase 2 study in ObesityNCT07055516 · 176 enrolled · United States
- Oct 17, 2025Phase 2 study in ObesityNCT07220629 · 82 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07220629Obesity · United States | 2 | Completed | Aug 21, 2026 | 82 |
| NCT07055516Obesity · United States | 2 | Completed | May 27, 2026 | 176 |
| NCT06129409Cardiovascular Diseases · United States | 1 | Completed | Apr 15, 2024 | 67 |
How it is read
Names in the registry
- “NT-0796”, 3 entries
Conditions, from the studies’ own filings
- Obesity, 2 studies
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.